[go: up one dir, main page]

SG11201503271XA - Compositions and methods for modulating cell signaling - Google Patents

Compositions and methods for modulating cell signaling

Info

Publication number
SG11201503271XA
SG11201503271XA SG11201503271XA SG11201503271XA SG11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA
Authority
SG
Singapore
Prior art keywords
compositions
methods
cell signaling
modulating cell
modulating
Prior art date
Application number
SG11201503271XA
Inventor
Timothy Alan Springer
Leonard Ira Zon
Nagesh K Mahanthappa
Original Assignee
Scholar Rock Inc
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc, Childrens Medical Center filed Critical Scholar Rock Inc
Publication of SG11201503271XA publication Critical patent/SG11201503271XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201503271XA 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling SG11201503271XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722969P 2012-11-06 2012-11-06
US201261722919P 2012-11-06 2012-11-06
PCT/US2013/068613 WO2014074532A2 (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Publications (1)

Publication Number Publication Date
SG11201503271XA true SG11201503271XA (en) 2015-05-28

Family

ID=50685303

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201503271XA SG11201503271XA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling
SG10201704616SA SG10201704616SA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704616SA SG10201704616SA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Country Status (10)

Country Link
US (2) US20150284455A1 (en)
EP (1) EP2916867A4 (en)
JP (3) JP2016500704A (en)
AU (3) AU2013341353B2 (en)
CA (2) CA2890733A1 (en)
IL (1) IL238488B (en)
MX (1) MX388059B (en)
SG (2) SG11201503271XA (en)
WO (1) WO2014074532A2 (en)
ZA (1) ZA201502884B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
UA121453C2 (en) 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY
KR102385507B1 (en) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
JP6774164B2 (en) 2012-08-24 2020-10-21 中外製薬株式会社 Mouse FcγRII specific Fc antibody
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
WO2014163101A1 (en) 2013-04-02 2014-10-09 中外製薬株式会社 Fc region variant
PT2981822T (en) 2013-05-06 2020-12-07 Scholar Rock Inc Compositions and methods for growth factor modulation
JP7348708B2 (en) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Combination vaccine device and method for killing cancer cells
AU2015342936B2 (en) * 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
ES2941897T3 (en) 2014-11-12 2023-05-26 Seagen Inc Compounds that interact with glycans and procedures for use
JP6227191B1 (en) * 2014-12-19 2017-11-08 中外製薬株式会社 Anti-myostatin antibody, polypeptide comprising mutant Fc region, and method of use
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
CN114773470A (en) 2015-02-05 2022-07-22 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
JP2018527903A (en) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． GDF11 binding protein and use thereof
AU2016323447B2 (en) 2015-09-15 2023-03-30 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
TWI836305B (en) 2015-09-24 2024-03-21 日商第一三共股份有限公司 Anti-garp antibody and producing method and use thereof
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
SG11201805709RA (en) 2016-01-08 2018-07-30 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof
CN115531609A (en) 2016-02-06 2022-12-30 哈佛学院校长同事会 Remodeling hematopoietic niches to reconstitute immunity
US11643459B2 (en) 2016-03-11 2023-05-09 Scholar Rock, Inc. TGFβ1-binding immunoglobulins and use thereof
KR102209363B1 (en) * 2016-03-31 2021-01-29 장슈 야홍 메디텍 코퍼레이션 리미티드 Combinational uses of nitroxoline and its analogues with chemotherapeis and immunotherapies in the treatment of cancers
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
CN115537372A (en) 2016-07-13 2022-12-30 哈佛学院院长等 Antigen-presenting cell mimic scaffold and methods for its preparation and use
WO2018026884A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd A preparation for the prevention or treatment of diseases related to il-8
EP3512887B1 (en) 2016-09-15 2024-07-31 Acceleron Pharma Inc. A fusion protein for use in treating anemia comprising twsg and fc
CA3088855A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
EP3612625A4 (en) 2017-04-21 2021-08-18 Mellitus, LLC Methods and antibodies for diabetes-related applications
SI3621694T1 (en) 2017-05-09 2023-10-30 Scholar Rock, Inc Lrrc33 inhibitors and use thereof
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
WO2019148194A2 (en) * 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CAL-PDZ BINDING DOMAIN CYCLIC PEPTIDYL INHIBITORS
HUE056501T2 (en) 2018-07-11 2022-02-28 Scholar Rock Inc Isoform selective tgfbeta1 inhibitors and use thereof
EP3820508A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. High-affinity, isoform-selective tgf?1 inhibitors and use thereof
IL317123A (en) 2018-08-27 2025-01-01 Regeneron Pharma Use of Raman Spectroscopy in Downstream Purification
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
TW202035445A (en) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 Anti-lap antibody variants and uses thereof
MX2021009175A (en) 2019-01-30 2021-09-14 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFß AND USES THEREOF.
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
US20220308072A1 (en) 2019-08-12 2022-09-29 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
PE20221447A1 (en) 2019-08-28 2022-09-21 Chugai Pharmaceutical Co Ltd LATENT ANTI-TGF-BETA 1 ANTIBODIES AND METHODS OF USE
JP2022549270A (en) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ Biomaterial-based non-antigen vaccine and its use
CN111474336B (en) * 2020-03-21 2023-07-28 南昌大学 A preparation method of nickel ferricyanide nanoparticle chemiluminescent aptasensor and a method for detecting 8-OhdG based on it
WO2022099093A1 (en) * 2020-11-06 2022-05-12 President And Fellows Of Harvard College Scaffolds for enhancing neutrophils and uses thereof
WO2022132666A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
CN113061575B (en) * 2021-03-25 2023-04-07 中国人民解放军陆军军医大学 Method for separating and purifying inherent lymphoid cells from colon inherent layer of old mouse
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
CN115286701A (en) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 A target for regulating intestinal mucosal homeostasis or inflammatory bowel disease in mammals and its application
TW202430247A (en) 2022-12-22 2024-08-01 美商供石公司 Selective and potent inhibitors of myostatin activation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP3452946B2 (en) * 1992-02-19 2003-10-06 協和醗酵工業株式会社 Anti-TGF-β masking protein monoclonal antibody
AU5587094A (en) * 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
US5972335A (en) * 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
US5616561A (en) * 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO2005013915A2 (en) * 2003-08-08 2005-02-17 The Regents Of The University Of California Novel indications for transforming growth factor-beta regulators
WO2006106599A1 (en) * 2005-03-01 2006-10-12 Kyoto University Pharmaceutical for preventing and/or treating disease caused by abnormal enhancement of extracellular domain shedding
US8597646B2 (en) * 2005-10-25 2013-12-03 The Johns Hopkins University Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
AU2009223115B2 (en) * 2008-03-14 2015-09-24 Humanzyme, Inc. Recombinant production of authentic human proteins using human cell expression systems
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials

Also Published As

Publication number Publication date
AU2017203805A1 (en) 2017-06-22
IL238488A0 (en) 2015-06-30
AU2017203805B2 (en) 2019-08-15
SG10201704616SA (en) 2017-07-28
ZA201502884B (en) 2016-01-27
WO2014074532A2 (en) 2014-05-15
MX388059B (en) 2025-03-19
CA3023553A1 (en) 2014-05-15
AU2019264599A1 (en) 2019-12-05
AU2013341353B2 (en) 2017-03-16
JP2017132796A (en) 2017-08-03
IL238488B (en) 2020-04-30
JP2016500704A (en) 2016-01-14
EP2916867A2 (en) 2015-09-16
US20200024339A1 (en) 2020-01-23
WO2014074532A3 (en) 2014-06-26
EP2916867A4 (en) 2016-10-05
JP2019163317A (en) 2019-09-26
US20150284455A1 (en) 2015-10-08
CA2890733A1 (en) 2014-05-15
MX2015005675A (en) 2016-02-03
AU2013341353A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
ZA201502884B (en) Compositions and methods for modulating cell signaling
ZA201409229B (en) Compositions and methods for modulating utrn expression
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
SG11201408697QA (en) Methods and compositions for natural killer cells
IL238266A0 (en) Compositions for modulating c9orf72 expression
SG10201702387YA (en) Cell lines
IL237156B (en) Microcapsule compositions and methods
PT2906696T (en) Methods for modulating c9orf72 expression
ZA201300319B (en) Compositions and methods for modulating the wnt signaling pathway
IL236679A0 (en) Compositions and methods for regulating car t cells
IL236158A0 (en) Methods and compositions for biomethane production
EP2850187A4 (en) Compositions and methods for modulating pten expression
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
PT3636274T (en) Compositions and methods for modulating gamma-c-cytokine activity
GB201222658D0 (en) Closure arrangements
IL234683A0 (en) Methods and compositions for modulating toso activity
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
EP2909309A4 (en) Compositions and methods for vitamin-rich fermentates
GB201222406D0 (en) Gel compositions
ZA201504144B (en) Gel compositions
EP2885001A4 (en) Novel cell compositions and methods
GB2511165B (en) Multi-sash closure system
GB201222405D0 (en) Gel compositions
EP2827861A4 (en) Composition and methods for cell modulation